Hematology, transfusion and cell therapy · 2026
Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dos Anjos Arthur Sousa, Mendonça Claudio Verti, Maradei Simone Cunha, de Azevedo Juliana Pessoa Rivello, Kaufman Jacques, Moreira Maria Claudia, Morgado Monique, Garnica Marcia, Maiolino Angelo
Аннотация
INTRODUCTION: Daratumumab, an Anti-CD38 monoclonal antibody, is now widely used in frontline induction for transplant-eligible multiple myeloma. Although highly effective, concerns remain regarding its potential impact on CD34⁺ stem cell mobilization and early outcomes after autologous hematopoietic stem cell transplantation, particularly when combined with lenalidomide. This study aims to evaluate whether prior daratumumab exposure affects CD34⁺ mobilization, stem cell collection, engraftment, or early post-autologous hematopoietic stem cell transplantation complications.
METHODS: a retrospective, single-center cohort study was conducted in 100 adults who underwent autologous hematopoietic stem cell transplantation. Data on mobilization, CD34⁺ counts, plerixafor use, collection yield, engraftment, infectious complications, engraftment syndrome, intensive care unit admission, and hospitalization were extracted from medical records.
RESULTS: Of the 100 patients, 46% had received daratumumab therapy. Baseline characteristics were similar except for more frequent prior lenalidomide use in controls (78% versus 35%; p < 0.001). No mobilization failures occurred. Peripheral CD34⁺ levels during mobilization (15 versus 19 cells/µL; p = 0.220) were comparable. Plerixafor use (26% versus 24%; p = 1.0), final CD34⁺ yield (3.80 versus 4.07×10⁶ cells/kg; p = 0.358), and time to neutrophil engraftment (10 versus 10.5 days; p = 0.539) were statistically equivalent. Rates of engraftment syndrome (25%), febrile neutropenia (89%), bacteremia (23%), intensive care unit admission (12%), and hospitalization metrics did not differ significantly. One death occurred in the control group.
CONCLUSION: In this real-world cohort, no significant differences in CD34⁺ mobilization, apheresis outcomes, engraftment, or early post-autologous hematopoietic stem cell transplantation complications were observed based on prior daratumumab exposure. These findings support the safety and feasibility of autologous hematopoietic stem cell transplantation following anti-CD38-based induction regimens, including those incorporating lenalidomide.
METHODS: a retrospective, single-center cohort study was conducted in 100 adults who underwent autologous hematopoietic stem cell transplantation. Data on mobilization, CD34⁺ counts, plerixafor use, collection yield, engraftment, infectious complications, engraftment syndrome, intensive care unit admission, and hospitalization were extracted from medical records.
RESULTS: Of the 100 patients, 46% had received daratumumab therapy. Baseline characteristics were similar except for more frequent prior lenalidomide use in controls (78% versus 35%; p < 0.001). No mobilization failures occurred. Peripheral CD34⁺ levels during mobilization (15 versus 19 cells/µL; p = 0.220) were comparable. Plerixafor use (26% versus 24%; p = 1.0), final CD34⁺ yield (3.80 versus 4.07×10⁶ cells/kg; p = 0.358), and time to neutrophil engraftment (10 versus 10.5 days; p = 0.539) were statistically equivalent. Rates of engraftment syndrome (25%), febrile neutropenia (89%), bacteremia (23%), intensive care unit admission (12%), and hospitalization metrics did not differ significantly. One death occurred in the control group.
CONCLUSION: In this real-world cohort, no significant differences in CD34⁺ mobilization, apheresis outcomes, engraftment, or early post-autologous hematopoietic stem cell transplantation complications were observed based on prior daratumumab exposure. These findings support the safety and feasibility of autologous hematopoietic stem cell transplantation following anti-CD38-based induction regimens, including those incorporating lenalidomide.